Takatsuki, Japan

Chihiro Kusunoki

This inventor holds 1 USPTO granted patent. Top assignees: Abgenix, Inc., Japan Tobacco Inc.. Active years: 2012.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chihiro Kusunoki: Innovator in Monoclonal Antibody Preparation

Introduction

Chihiro Kusunoki is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of biotechnology, particularly in the preparation of monoclonal antibodies. His innovative methods have the potential to enhance the efficiency of antibody production, which is crucial for various medical applications.

Latest Patents

Kusunoki holds a patent for a "Method for preparing monoclonal antibody." This patent describes a process that significantly increases the yield of monoclonal antibodies from the culture medium of recombinant hybridoma. The method involves introducing genes that encode a protein identical to the immunoglobulin heavy chain polypeptide of the specific monoclonal antibody into an immortalized B cell, or hybridoma, that produces the monoclonal antibody. This advancement could lead to more effective therapies and diagnostics in the medical field.

Career Highlights

Throughout his career, Chihiro Kusunoki has worked with prominent companies such as Japan Tobacco Inc. and Abgenix, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in biotechnology.

Collaborations

Kusunoki has collaborated with various professionals in his field, including Atsushi Fukushima, who has been a significant coworker in his research endeavors.

Conclusion

Chihiro Kusunoki's innovative work in the preparation of monoclonal antibodies showcases his dedication to advancing biotechnology. His contributions are likely to have a lasting impact on the medical field, enhancing the development of effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…